An FDA advisory board recommended withdrawing government approval for the breast cancer drug, Avastin. Pros and cons of the decision and its implications for FDA’s accelerated approval process to treat serious and life threatening diseases.

Guests

  • Gardiner Harris Science reporter for "The New York Times" and author of the mystery novel 'Hazard.'
  • Dr. Carolyn Hendricks A medical oncologist affiliated with Suburban Hospital in Bethesda.
  • William Hubbard Former associate commissioner for the Food and Drug Administration; spokesperson for the Alliance for a Stronger FDA
  • Dr. Peter Bach Attending physician and director of the Center for Health Policy and Outcomes at Memorial Sloan-Kettering Cancer Center, and a former adviser to Medicare.

Topics + Tags

Most Recent Shows